MedTrace Logo

Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients

NCT00473655 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2010-12-16

Study results available
· View outcomes & findings →

Summary

The primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and 20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride levels.

Conditions

  • Hypertriglyceridemia
  • Hyperlipoproteinemia Type IV
  • Hyperlipoproteinemia Type V
  • Hyperlipoproteinemia Type IIb
  • Hyperlipidemia

Interventions

DRUG

rosuvastatin

10mg or 20mg

Sponsors & Collaborators

Principal Investigators

  • Ana Polanco, MD · AstraZeneca Mexico

  • Ana Polanco, MD · AstraZeneca Mexico

  • Juan Talavera, MD · IMSS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00473655 on ClinicalTrials.gov